Component

Candida albicans membrane integrity

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. CHD-FA exposure increased membrane permeability in Candida albicans assays.

    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Clinical Candida isolate panel; planktonic and biofilm growth; inhibitory concentrations reported as 0.125% and 0.25%.
    limitations
    An in-vitro antiseptic concentration is not a systemic supplement exposure or demonstrated infection treatment.
    nutrient_topic
    Fulvic acid collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Fulvic acid (heterogeneous humic fraction)
    plain_language
    The tested antifungal action involved a leaky membrane.
    primary_references
    Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22479260/ · DOI 10.3389/fmicb.2012.00116

    Fulvic acid: mixture identity, mineral chemistry, signaling and cross-nutrient mechanisms (2026-09-19) · lines 124–130

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Clinical Candida isolate panel; planktonic and biofilm growth; inhibitory concentrations reported as 0.125% and 0.25%. · source_derived_draft · unverified_draft

    ## fulvic-acid-fungal-membrane The tested antifungal action involved a leaky membrane. CHD-FA exposure increased membrane permeability in Candida albicans assays. Model: Clinical Candida isolate panel; planktonic and biofilm growth; inhibitory concentrations reported as 0.125% and 0.25%. Limitations: An in-vitro antiseptic concentration is not a systemic supplement exposure or demonstrated infection treatment. Evidence access: Primary full text Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22479260/ · DOI 10.3389/fmicb.2012.00116
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards